CJC-1295 No DAC Dosing Protocol

CJC-1295 No DAC dosing protocol centers on Modified GRF 1-29, a short-acting growth hormone stimulator used in peptide research for pulsatile GH release. The "No DAC" distinction matters: the DAC version (Drug Affinity Complex) attaches to a blood protein that keeps it active for days, while this version clears your system in about 30 minutes — delivering a quick growth hormone pulse and then fading.

CJC-1295 No DAC is a modified version of your body's natural growth-hormone-releasing hormone (GHRH). Scientists made four small changes to the original molecule to make it more resistant to the enzymes that would normally break it down within seconds. The result is a compound that lasts about 30 minutes per dose — long enough to trigger a meaningful growth hormone pulse, but short enough to clear quickly and let your body return to baseline before the next dose.

The short half-life is often considered a feature rather than a limitation: it supports discrete GH pulses and easier titration, with rapid resolution if side effects occur.

CJC-1295 No DAC is frequently paired with Ipamorelin because the peptides target complementary pathways (GHRH receptor plus ghrelin receptor), producing synergistic GH release in research protocols.

This compound is not FDA-approved and has no active clinical development pathway. All information on this page is educational and research-reference only.

The table below shows how much liquid to draw from your syringe for each common dose, based on your vial size and how much bacteriostatic (BAC) water you add. Find your vial size in the left column, then read across to your target dose. The "units" number is what you'll see on a standard U-100 insulin syringe.

CJC-1295 No DAC is generally considered better tolerated for rapid titration because of short half-life and fast clearance.

Common effects: Transient flushing, mild injection-site reactions, headache, and occasional water retention are most often reported.

Dose-dependent pattern: Higher per-injection doses tend to produce more flushing/headache without linear GH benefit in many users.

Resolution window: Most adverse effects resolve within 30-60 minutes, a key contrast versus long-acting DAC exposure.

Cardiovascular context: A Phase 2 trial of CJC-1295 with DAC was stopped after one participant had a heart attack (later deemed unrelated by investigators). This event is associated with the DAC version specifically — no similar safety signal has been reported in No DAC research.

Contraindication context: Protocols typically exclude active cancer, meaningful cardiovascular disease, glucose dysregulation, pregnancy, and peptide hypersensitivity.

CJC-1295 No DAC clinical trial data comes primarily from studies on the parent CJC-1295 molecule in the mid-2000s. No large outcome trials have been conducted specifically on the "No DAC" variant. The table below summarizes the key published studies — note that the Phase 2 trial was halted early due to a safety event (later deemed unrelated to the compound by investigators).

No large clinical trial has been conducted specifically on the No DAC version of CJC-1295. Current dosing protocols are based on the published CJC-1295 research above, combined with the understanding that the No DAC version works through the same mechanism but clears much faster. This means dosing frequency and timing are adjusted accordingly, but the underlying science supporting growth hormone release is the same.

CJC-1295 No DAC belongs to a family of growth hormone stimulators. The table below compares it to the three compounds it's most often discussed alongside: CJC-1295 with DAC (its long-acting sibling), Sermorelin (an older, shorter-acting alternative), and Ipamorelin (a different type of GH stimulator that works through a separate receptor). The key differences are half-life, dosing frequency, and how each one releases growth hormone.

No DAC and Sermorelin are both GHRH analogs, but No DAC has longer short-acting exposure than Sermorelin and is often favored in research stacks.

DAC is more convenient but less physiologically pulsatile. Ipamorelin complements No DAC via a separate receptor pathway.

Reconstitution math differs across compounds; use calculator support for concentration-specific dosing.

See the CJC-1295 with DAC, Sermorelin and Ipamorelin for compound-specific guides.